Arrowhead Pharmaceuticals (NASDAQ:ARWR) shares rise 23% after Plozasiran Phase 3 data released

Arrowhead’s stock jumped as the SHASTA-3 and SHASTA-4 studies achieved all their prespecified endpoints. The latest quoted price was recorded at 13:52 EDT.

NASDAQ:ARWR · Pharmaceutical Industry · Stock Market
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals, Inc. is ending 2025 in rare biotech air. The RNA interference specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a new Alzheimer’s disease trial — all while its share price hovers near record highs. Arrowhead Pharmaceuticals, Inc.+2Arrowhead Pharmaceuticals+2
9 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference specialist climbed to a new 52‑week high near $69 per share after the company announced it had dosed the first subjects in its Alzheimer’s disease trial ARO‑MAPT and highlighted a string of recent FDA victories and deal-driven cash inflows. Arrowhead Pharmaceuticals, Inc.+2MarketBeat+2
8 December 2025
·
Follow on Google News
Add as preferred source Open in Google News